Skip to content


  • Poster presentation
  • Open Access

HLA-G 3142C/G polymorphism is related to development of symptoms in HTLV-1 infected individuals

  • 1,
  • 2, 3Email author,
  • 4,
  • 2,
  • 1,
  • 1, 2,
  • 2, 3 and
  • 1
Retrovirology201411 (Suppl 1) :P74

  • Published:


  • Human Leukocyte
  • 3142GG Genotype
  • Related Disease
  • Immunosuppressive Effect
  • Proviral Load

The majority of HTLV-1 infected individuals remain asymptomatic (HAC) throughout life, and the risk factors associated to the development of related diseases, such as HAM/TSP and ATL, are not fully understood. The human leukocyte antigen-G (HLA-G) is expressed in several pathological conditions and it has been associated to immunosuppressive effects allowing the virus-infected cells to escape of the host antiviral defense. Here, we evaluated the correlation between HLA-G polymorphisms in symptomatic and asymptomatic HTLV-1 infected individuals. Four polymorphisms of the exon 8 of the HLA-G gene were analysed by gene sequencing in HAC (n=48) and HAM/TSP patients (n=43). No difference was found between the groups for 3035C/T, 3187A/G and 3196C/G polymorphisms. On the other hand, despite of the absence of statistical significance, HAC group showed higher frequency of the 3142GG genotype (responsible for decreased transcription of theHLA-G) compared to HAM/TSP group (p=0,0607). Still, HAC group showed lower frequency of the 3142CC genotype (responsible for increased transcription of the HLA-G) compared to HAM/TSP group (p=0,0762). Furthermore, HAC group showed statistically higher frequency of the 3142G allele and lower frequency of the 3142C allele compared to HAM/TSP group (p=0,0244). In conclusion, HTLV-1-related symptoms in HAM/TSP group could be partially determined by higher expression of HLA-G (caused by higher frequency of the 3142C allele). We hypothesise that the higher expression of HLA-G protects the HTLV-1 infected cell against immune system attack the increasing proviral load and trigger the HAM/TSP symptoms.

Financial support


Authors’ Affiliations

Faculdade de Medicina de Ribeirão Preto – USP, Ribeirão Preto, São Paulo, Brazil
Fundação Hemocentro de Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil
Faculdade de Ciências Farmacêuticas de Ribeirão Preto – USP, Ribeirão Preto, São Paulo, Brazil
Faculdade de Ceilândia – UNB/FCE, Universidade de Brasília, Brasília, Distrito Federal, Brazil